CD8A and neoplasm: GEN1046 significantly enhanced intratumoral CD8+ T-cell counts in MC38-hPD-L1 tumor–bearing mice, a finding that can be attributed to the combination of PD-L1 blockade with 4-1BB agonist activity, as PD-L1 blockade alone with a durvalumab analogue had no such effect.